

# Stuart J Pocock

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8240246/stuart-j-pocock-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

387 papers	81,899 citations	97 h-index	285 g-index
414 ext. papers	104,337 ext. citations	11.4 avg, IF	7.75 L-index

#	Paper	IF	Citations
387	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Lancet, The</i> , <b>2007</b> , 370, 1453-7	40	5729
386	Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1597-607	59.2	4801
385	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Journal of Clinical Epidemiology</i> , <b>2008</b> , 61, 344-9	5.7	4750
384	Transcatheter versus surgical aortic-valve replacement in high-risk patients. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2187-98	59.2	4230
383	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 311-22	59.2	3606
382	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. <i>International Journal of Surgery</i> , <b>2014</b> , 12, 1495-9	7.5	3267
381	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 573-7	8	2941
380	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>BMJ, The</i> , <b>2007</b> , 335, 806-8	5.9	2821
379	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>PLoS Medicine</i> , <b>2007</b> , 4, e296	11.6	2066
378	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>PLoS Medicine</i> , <b>2007</b> , 4, e297	11.6	1900
377	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 11-21	59.2	1890
376	Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1695-1705	59.2	1849
375	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , <b>2003</b> , 362, 759-66	40	1506
374	Bivalirudin during primary PCI in acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2218-30	59.2	1457
373	Ferric carboxymaltose in patients with heart failure and iron deficiency. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2436-48	59.2	1178
372	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>Epidemiology</i> , <b>2007</b> , 18, 805-35	3.1	1174
371	Bivalirudin for patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2203-16	59.2	1167

370	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1413-1424	59.2	1099
369	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , <b>2009</b> , 373, 2125-35	40	1059
368	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>International Journal of Surgery</i> , <b>2014</b> , 12, 1500-24	7.5	1057
367	Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1152-60	27.4	908
366	Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2235-45	59.2	905
365	Subgroup analysis and other (mis)uses of baseline data in clinical trials. <i>Lancet, The</i> , <b>2000</b> , 355, 1064-9	40	878
364	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , <b>2014</b> , 35, 2383-431	9.5	849
363	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, W163-94	8	765
362	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Epidemiology</i> , <b>2007</b> , 18, 800-4	3.1	763
361	Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. <i>Statistics in Medicine</i> , <b>2002</b> , 21, 2917-30	2.3	749
360	Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2594-604	27.4	710
359	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , <b>2006</b> , 27, 65-75	9.5	680
358	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Preventive Medicine</i> , <b>2007</b> , 45, 247-51	4.3	630
357	Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 40-7	15.1	630
356	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Bulletin of the World Health Organization</i> , <b>2007</b> , 85, 867-72	8.2	613
355	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2223-2235	59.2	603
354	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , <b>2013</b> , 34, 1404-13	9.5	595
353	Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1946-59	59.2	577

352	Statistical problems in the reporting of clinical trials. A survey of three medical journals. <i>New England Journal of Medicine</i> , <b>1987</b> , 317, 426-32	59.2	549
351	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. <i>Lancet, The</i> , <b>2009</b> , 373, 1190-7	40	531
350	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , <b>1992</b> , 11, 1685-704	2.3	500
349	A risk score to predict bleeding in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2556-66	15.1	479
348	Randomized trials or observational tribulations?. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1907-9	59.2	452
347	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2160-2170	40	406
346	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , <b>2013</b> , 382, 1714-22	40	405
345	Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2435-45	15.1	403
344	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , <b>2007</b> , 116, 1482-7	16.7	400
343	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2032-2042	59.2	395
342	Bivalirudin started during emergency transport for primary PCI. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2207-17	59.2	372
341	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 2193-204	40	358
340	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2346-2355	40	358
339	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , <b>2020</b> , 396, 819-829	40	355
338	Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>2015</b> , 385, 1729-1737	40	351
337	Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. <i>Lancet, The</i> , <b>2002</b> , 359, 1686-9	40	328
336	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2224-2234	15.1	306
335	Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiogram to reduced clinical events), ACUTY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 644-64	5	274

334	Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 345-357	15.1	267
333	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1820-1830	59.2	265
332	Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , <b>2007</b> , 116, 627-36	16.7	264
331	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUTY trial. <i>European Heart Journal</i> , <b>2009</b> , 30, 1457-66	9.5	260
330	Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the Biolmage study. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1065-74	15.1	256
329	Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1298-1310	15.1	252
328	Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. <i>Circulation</i> , <b>2013</b> , 128, 1495-503	16.7	249
327	BMI and risk of dementia in two million people over two decades: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 431-436	18.1	247
326	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 170-7	12.3	247
325	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. <i>Circulation</i> , <b>2015</b> , 131, 2104-13	16.7	239
324	The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. <i>European Heart Journal</i> , <b>2012</b> , 33, 176-82	9.5	231
323	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUTY Timing trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 591-602	27.4	226
322	A polypill strategy to improve adherence: results from the FOCUS project. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2071-82	15.1	202
321	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2107-2115	40	195
320	Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Circulation</i> , <b>2006</b> , 113, 986-94	16.7	194
319	Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. <i>European Heart Journal</i> , <b>2007</b> , 28, 1936-43	9.5	192
318	Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , <b>2007</b> , 115, 3111-20	16.7	188
317	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 125-133	12.3	186

316	Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUTY trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 2497-506	27.4	185
315	Adaptive increase in sample size when interim results are promising: a practical guide with examples. <i>Statistics in Medicine</i> , <b>2011</b> , 30, 3267-84	2.3	184
314	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , <b>2019</b> , 140, 240-261	16.7	183
313	Issues in the reporting of epidemiological studies: a survey of recent practice. <i>BMJ, The</i> , <b>2004</b> , 329, 883	5.9	183
312	A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. <i>BMJ: British Medical Journal</i> , <b>2001</b> , 323, 75-81		170
311	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , <b>2019</b> , 40, 2632-2653	9.5	169
310	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1444-1451	4.0	166
309	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1895-1904	4.0	162
308	Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2979-2991	15.1	153
307	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2791-2802	15.1	152
306	The Primary Outcome Fails - What Next?. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 861-70	59.2	152
305	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1082-94	12.3	143
304	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 33-40	12.3	141
303	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , <b>2008</b> , 29, 2641-50	9.5	135
302	Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 427-437	6.7	134
301	Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners. <i>Biometrics</i> , <b>1987</b> , 43, 213	1.8	134
300	Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 23-32	15.1	132
299	Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2256-62	15.1	125



298	Insulin glargine and malignancy: an unwarranted alarm. <i>Lancet, The</i> , <b>2009</b> , 374, 511-3	40	112
297	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1390-1400	12.3	111
296	The agonising negative trend in monitoring of clinical trials. <i>Lancet, The</i> , <b>1999</b> , 354, 1983-8	40	111
295	When (not) to stop a clinical trial for benefit. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 2228-30	27.4	109
294	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , <b>2016</b> , 171, 82-91	4.9	104
293	Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circulation</i> , <b>2010</b> , 121, 43-51	16.7	100
292	Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 1146-55	5	98
291	Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, 698-705	8	94
290	2-Year Outcomes of High 'Bleeding' Risk Patients After Polymer-Free Drug-Coated Stents. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 162-171	15.1	91
289	The pros and cons of noninferiority trials. <i>Fundamental and Clinical Pharmacology</i> , <b>2003</b> , 17, 483-90	3.1	90
288	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. <i>BMJ, The</i> , <b>2005</b> , 331, 869	5.9	87
287	Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 289-97	7.9	84
286	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , <b>2016</b> , 182, 125-134	4.9	84
285	Trials stopped early: too good to be true?. <i>Lancet, The</i> , <b>1999</b> , 353, 943-4	40	83
284	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 337-349	16.7	80
283	Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1273-1285	15.1	79
282	The Primary Outcome Is Positive - Is That Good Enough?. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 971-9	59.2	78
281	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 326-336	16.7	74

280	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1278	12.3	73
279	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 150	8.7	73
278	Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. <i>Lancet, The</i> , <b>2018</b> , 391, 850-859	40	72
277	Estimation issues in clinical trials and overviews. <i>Statistics in Medicine</i> , <b>1990</b> , 9, 657-71	2.3	70
276	Categorisation of continuous risk factors in epidemiological publications: a survey of current practice. <i>Epidemiologic Perspectives and Innovations</i> , <b>2010</b> , 7, 9		68
275	The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 300	2.8	63
274	Stent-Related Adverse Events >1 Year After Percutaneous 'Coronary' Intervention. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 590-604	15.1	61
273	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 2823-9	9.5	61
272	Current controversies in data monitoring for clinical trials. <i>Clinical Trials</i> , <b>2006</b> , 3, 513-21	2.2	61
271	Diagnostic and Prognostic Implications of 'Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1670-80	5	59
270	Ticagrelor With or Without Aspirin After Complex 'PCI. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2414-2424	15.1	58
269	Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2648-2662	15.1	57
268	Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 15-20	15.1	56
267	Statistical and ethical issues in monitoring clinical trials. <i>Statistics in Medicine</i> , <b>1993</b> , 12, 1459-69; discussion 1471-5	2.3	56
266	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1186-1197	12.3	55
265	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. <i>Circulation</i> , <b>2021</b> , 143, 310-321	16.7	55
264	Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. <i>International Journal of Cardiology</i> , <b>2017</b> , 245, 27-34	3.2	54
263	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 27-38	15.1	54



262	Translating statistical findings into plain English. <i>Lancet, The</i> , <b>2009</b> , 373, 1926-8	4.0	54
261	Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. <i>American Journal of Cardiology</i> , <b>2004</b> , 94, 1023-7	3	54
260	Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-term follow up of antithrombotic management patterns in acute coronary syndrome patients) study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 509-17	4.3	52
259	Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>American Heart Journal</i> , <b>2012</b> , 163, 522-9	4.9	52
258	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 557-65	12.3	51
257	The hope and the hazards of using compliance data in randomized controlled trials. <i>Statistics in Medicine</i> , <b>1998</b> , 17, 303-17	2.3	46
256	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, 629-637	2.7	45
255	Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. <i>European Heart Journal</i> , <b>2017</b> , 38, 961-969	9.5	45
254	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , <b>2020</b> , 41, 3743-3749	9.5	45
253	Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis: The PESA Study. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 2467-76	15.1	44
252	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , <b>2019</b> ,	9.5	44
251	Do current clinical trials meet society's needs?: a critical review of recent evidence. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1615-28	15.1	44
250	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 743-751	9.5	44
249	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. <i>Lancet, The</i> , <b>2018</b> , 392, 1127-1137	4.0	43
248	Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. <i>Statistics in Medicine</i> , <b>1997</b> , 16, 2855-72	2.3	43
247	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2020</b> , 41, 2109-2117	9.5	42
246	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. <i>International Journal of Stroke</i> , <b>2016</b> , 11, 683-94	6.3	42
245	The perils of surrogate endpoints. <i>European Heart Journal</i> , <b>2015</b> , 36, 2212-8	9.5	41

244	Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. <i>PLoS ONE</i> , <b>2017</b> , 12, e0164608	3.7	41
243	The simplest statistical test: how to check for a difference between treatments. <i>BMJ, The</i> , <b>2006</b> , 332, 1256-8	5.9	41
242	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2383-2392	12.3	41
241	10-Year Mortality Outcome of a Routine 'Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 511-20	15.1	40
240	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 754-765	15.1	39
239	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1546-1552	14.6	38
238	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , <b>2018</b> , 138, 570-577	16.7	38
237	Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2757-2766	15.1	38
236	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1188-1196	3.2	37
235	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1616-1628	15.1	37
234	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , <b>2015</b> , 36, 1106-14	9.5	37
233	International differences in treatment effect: do they really exist and why?. <i>European Heart Journal</i> , <b>2013</b> , 34, 1846-52	9.5	37
232	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , <b>2020</b> , 41, 3533-3545	9.5	37
231	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 504-510	12.3	37
230	International patterns of dual antiplatelet therapy duration after acute coronary syndromes. <i>Heart</i> , <b>2017</b> , 103, 132-138	5.1	36
229	Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2016-2025	15.1	36
228	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 3-12	4.3	36
227	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1349-57	5	36

226	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 671-680	9.5	36
225	Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2536-49	15.1	35
224	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1846-1857	15.1	34
223	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2403-2413	15.1	34
222	Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published trials. <i>Stroke</i> , <b>2008</b> , 39, 2817-23	6.7	34
221	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 1203-1212	9.5	34
220	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , <b>2017</b> , 38, 1048-1055	9.5	33
219	Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2886-2898	15.1	33
218	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1397-1407	15.1	32
217	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 151, 20-32	7.4	31
216	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , <b>2014</b> , 175, 30-7	3.2	31
215	Predicting Subclinical Atherosclerosis in Low-Risk Individuals: Ideal Cardiovascular Health Score and Fuster-BEWAT Score. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2463-2473	15.1	31
214	Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. <i>Statistics in Medicine</i> , <b>2016</b> , 35, 2195-205	2.3	31
213	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 389-399	6.7	31
212	Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 2102-2112	15.1	30
211	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1381-1392	15.1	30
210	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> , 144, 1284-1294	16.7	30
209	Randomized trials, statistics, and clinical inference. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 428-31	15.1	29

208	The data monitoring experience in the MOXCON trial. <i>European Heart Journal</i> , <b>2004</b> , 25, 1974-8	9.5	29
207	Prediction of short-term survival with an application in primary biliary cirrhosis. <i>Statistics in Medicine</i> , <b>1992</b> , 11, 1731-45	2.3	29
206	The rise, fall, and possible resurrection of renal denervation. <i>Nature Reviews Cardiology</i> , <b>2016</b> , 13, 238-44	14.8	28
205	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , <b>2018</b> , 16, 116	11.4	28
204	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 345-351	12.3	28
203	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1803-1813	12.3	27
202	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 1461-9	5	27
201	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 2017-2025	5	27
200	A win ratio approach to comparing continuous non-normal outcomes in clinical trials. <i>Pharmaceutical Statistics</i> , <b>2016</b> , 15, 238-45	1	27
199	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 375-387	5	26
198	Figures in clinical trial reports: current practice & scope for improvement. <i>Trials</i> , <b>2007</b> , 8, 36	2.8	26
197	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	26
196	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1609-1621	15.1	26
195	Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 111-119	3.3	26
194	Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction: A Randomized Trial. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1551-1561	15.1	25
193	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 895-902	7.6	25
192	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. <i>American Heart Journal</i> , <b>2016</b> , 171, 40-7	4.9	24
191	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Circulation</i> , <b>2021</b> , 144, 1476-1484	16.7	24

190	More on subgroup analyses in clinical trials. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2076; author reply 2076-7	59.2	23
189	The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , <b>2005</b> , 149, 939-43	4.9	23
188	Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials. <i>Statistics in Medicine</i> , <b>2005</b> , 24, 3805-21	2.3	23
187	Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation. <i>Statistics in Medicine</i> , <b>2001</b> , 20, 2995-3008	2.3	23
186	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , <b>2013</b> , 166, 629-35	4.9	21
185	Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long-term follow-up of antithrombotic management patterns in Acute CORonary Syndrome patients in Asia). <i>Clinical Cardiology</i> , <b>2015</b> , 38, 511-9	3.3	21
184	Statistical reporting of clinical trials with individual changes from allocated treatment. <i>Statistics in Medicine</i> , <b>1996</b> , 15, 249-62	2.3	21
183	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2909-2919	15.1	21
182	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2016</b> , 2, 200-5	6.4	21
181	Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 727-737	4.3	21
180	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , <b>2017</b> , 188, 73-81	4.9	20
179	In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1454-1461	15.1	20
178	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , <b>2015</b> , 36, 2310-7	9.5	20
177	Data monitoring in randomized controlled trials: surveys of recent practice and policies. <i>Clinical Trials</i> , <b>2005</b> , 2, 22-33	2.2	20
176	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , <b>2017</b> , 236, 54-60	3.2	19
175	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2474-2485	6.7	19
174	Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). <i>International Journal of Stroke</i> , <b>2015</b> , 10, 1159-65	6.3	19
173	Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. <i>International Journal of Stroke</i> , <b>2015</b> , 10, 449-51	6.3	19



172	Large streamlined trials in cardiovascular disease. <i>European Heart Journal</i> , <b>2014</b> , 35, 544-8	9.5	19
171	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , <b>2009</b> , 30, 338-45	9.5	19
170	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , <b>1994</b> , 13, 197-8	2.3	19
169	External Validation of the MEESSE Acute Heart Failure Risk Score: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 248-256	8	19
168	Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 121-129	4.3	19
167	Empagliflozin and Major Renal Outcomes in Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1531-1533	59.2	19
166	Association Between a Social-Business Eating Pattern and Early Asymptomatic Atherosclerosis. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 805-14	15.1	18
165	Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 428-33	3	18
164	When to stop a clinical trial early for benefit: lessons learned and future approaches. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 294-302	7.6	18
163	Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 836-844	6.1	17
162	How to interpret figures in reports of clinical trials. <i>BMJ, The</i> , <b>2008</b> , 336, 1166-9	5.9	17
161	Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , <b>2004</b> , 1, 162-9	2.2	17
160	VALIDATION OF A QUESTIONNAIRE TO MEASURE OVERALL MEDITERRANEAN LIFESTYLE HABITS FOR RESEARCH APPLICATION: THE MEDITERRANEAN LIFESTYLE INDEX (MEDLIFE). <i>Nutricion Hospitalaria</i> , <b>2015</b> , 32, 1153-63	1	17
159	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	17
158	Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2957-2969	15.1	16
157	A major trial needs three statisticians: why, how and who?. <i>Statistics in Medicine</i> , <b>2004</b> , 23, 1535-9	2.3	16
156	Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , <b>2014</b> , 28, 349-59	1.5	16
155	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1468-1483	15.1	16



154	The win ratio approach for composite endpoints: practical guidance based on previous experience. <i>European Heart Journal</i> , <b>2020</b> , 41, 4391-4399	9.5	16
153	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , <b>2021</b> , 231, 121-127	4.9	16
152	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , <b>2017</b> , 38, 1632-1637	9.5	15
151	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2017</b> , 10, 645-654	5	15
150	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 718-727	12.3	15
149	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel	6.1	15
148	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 11, e001141	6	15
147	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). <i>Circulation: Cardiovascular Interventions</i> , <b>2017</b> , 10,	6	15
146	Infections Up to 76 Days After Stroke Increase Disability and Death. <i>Translational Stroke Research</i> , <b>2017</b> , 8, 541-548	7.8	15
145	Challenges in the Design and Interpretation of Noninferiority Trials: Insights From Recent Stent Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 894-903	15.1	15
144	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 707-16	12.3	15
143	Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. <i>Annals of Emergency Medicine</i> , <b>2019</b> , 73, 538-539	2.1	14
142	Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSE-AHF Scale. <i>Annals of Emergency Medicine</i> , <b>2019</b> , 74, 204-215	2.1	14
141	Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2740-2755	15.1	14
140	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 949-959	18.1	14
139	MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 1012-1021	7.9	14
138	Effectiveness and cost-effectiveness of a Yoga-based Cardiac Rehabilitation (Yoga-CaRe) program following acute myocardial infarction: Study rationale and design of a multi-center randomized controlled trial. <i>International Journal of Cardiology</i> , <b>2019</b> , 280, 14-18	3.2	14
137	Are risk minimization measures for approved drugs in Europe effective? A systematic review. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 443-454	4.1	13

136	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: findings from the EPICOR study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 254-62	4.3	13
135	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008603	6	13
134	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 319-329	3.8	13
133	Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , <b>2013</b> , 14, 401	2.8	13
132	Safety of drug-eluting stents: demystifying network meta-analysis. <i>Lancet, The</i> , <b>2007</b> , 370, 2099-100	40	13
131	Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 441-450	7.9	13
130	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 410-419	16.2	13
129	Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053). <i>International Journal of Stroke</i> , <b>2019</b> , 14, 191-206	6.3	13
128	Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability. <i>Emergencias</i> , <b>2019</b> , 31, 5-14	0.9	13
127	Statistical analysis plan for the 'Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage' (TICH-2) trial. <i>Trials</i> , <b>2017</b> , 18, 607	2.8	12
126	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1638-1646	3	12
125	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	12
124	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1175-81	12.3	11
123	Life as an academic medical statistician and how to survive it. <i>Statistics in Medicine</i> , <b>1995</b> , 14, 209-22	2.3	11
122	The role of external evidence in data monitoring of a clinical trial. <i>Statistics in Medicine</i> , <b>1996</b> , 15, 1285-93; discussion 1295-7	2.3	11
121	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , <b>2021</b> , 17, e898-e909	3.1	11
120	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 525-532	6.7	11
119	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. <i>Lancet, The</i> , <b>2022</b> , 399, 1401-1410	40	11

118	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007133	6	10
117	Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study. <i>International Journal of Cardiology</i> , <b>2017</b> , 243, 15-20	3.2	10
116	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2017</b> , 89, E217-E225	2.7	10
115	The science of risk models. <i>European Journal of Preventive Cardiology</i> , <b>2012</b> , 19, 7-13	3.9	10
114	Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-48	4.4	10
113	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1402-1411	12.3	10
112	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , <b>2019</b> , 275, 31-35	3.2	10
111	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1321-1332	15.1	10
110	Development of a Yoga-Based Cardiac Rehabilitation (Yoga-CaRe) Programme for Secondary Prevention of Myocardial Infarction. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2019</b> , 2019, 7470184	2.3	9
109	Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1903-9	2.5	9
108	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1615-1624	12.3	9
107	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008226	6	9
106	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2393-2398	12.3	9
105	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021965	6	9
104	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , <b>2017</b> , 243, 132-139	3.2	8
103	Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia. <i>BMC Cardiovascular Disorders</i> , <b>2018</b> , 18, 139	2.3	8
102	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , <b>2013</b> , 34, 1621-9	9.5	8
101	Relación entre las situaciones clínicas que llevan al tratamiento exclusivamente farmacológico del SCASEST y su pronóstico. <i>Revista Española De Cardiología</i> , <b>2017</b> , 70, 817-824	1.5	8

100	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 66-78	6.7	8
99	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1032-1041	16.2	8
98	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1337-1348	15.1	8
97	A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. <i>Drug Safety</i> , <b>2020</b> , 43, 623-633	5.1	7
96	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 87, 391-400	2.7	7
95	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 904-910	3	7
94	Rationale and design of the long-Term risk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dIsease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 1197-1204	3.3	7
93	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. <i>Lancet, The</i> , <b>2021</b> , 398, 1974-1983	4.0	7
92	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1529-1538	12.3	7
91	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 983-992	5	6
90	1-Year Clinical Outcomes of All 'Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 820-830	5	6
89	Effects of long-term use of cardiovascular drugs. <i>Lancet, The</i> , <b>2015</b> , 385, 325	4.0	6
88	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. <i>Health Technology Assessment</i> , <b>2018</b> , 22, 1-76	4.4	6
87	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 24-32	3.3	6
86	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4442-4451	9.5	6
85	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 93, E112-E119	2.7	6
84	Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. <i>World Journal of Urology</i> , <b>2020</b> , 38, 1221-1228	4	6
83	Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0208142	3.7	6

82	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , <b>2021</b> , 42, 4624-4634	9.5	6
81	Raised blood pressure and risk of dementia. <i>European Heart Journal</i> , <b>2019</b> , 40, 785-786	9.5	5
80	Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. <i>International Journal of Cardiology</i> , <b>2020</b> , 310, 16-22	3.2	5
79	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1661-1668	3	5
78	Oseltamivir for influenza - Authors' reply. <i>Lancet, The</i> , <b>2015</b> , 386, 1135-6	4.0	5
77	Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). <i>Trials</i> , <b>2015</b> , 16, 509	2.8	5
76	Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems?. <i>Journal of Cardiovascular Electrophysiology</i> , <b>1999</b> , 10, 1534-49	2.7	5
75	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , <b>2021</b> , 16, e1496-e1502	3.1	5
74	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 806-814	6.1	5
73	Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation. <i>Contemporary Clinical Trials Communications</i> , <b>2018</b> , 12, 176-181	1.8	5
72	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , <b>2021</b> , 42, 4683-4693	9.5	5
71	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4455-4464	9.5	5
70	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1028-1038	15.1	5
69	Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 999-1008	3.3	4
68	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , <b>2020</b> , 311, 7-14	3.2	4
67	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 725-734	6.1	4
66	Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial. <i>International Journal of Stroke</i> , <b>2017</b> , 12, 524-538	6.3	4
65	Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.. <i>European Journal of Heart Failure</i> , <b>2022</b> ,	12.3	4



64	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007347	7.6	4
63	Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. <i>Open Heart</i> , <b>2016</b> , 3, e000347	3	4
62	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 39-48	6.7	4
61	Statistical analysis plan for the 'Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)'. <i>European Stroke Journal</i> , <b>2018</b> , 3, 193-196	5.6	4
60	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1798-1799	12.3	4
59	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 42-51	5.1	3
58	Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study. <i>International Journal of Cardiology</i> , <b>2020</b> , 315, 1-8	3.2	3
57	Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 346-354	3.3	3
56	Ever-Pregnant Female Blood Donors and Mortality Risk in Male Recipients. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 1048	27.4	3
55	Individualizing treatment choices in the systolic blood pressure intervention trial. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 428-435	1.9	3
54	The Usefulness of the MEESSE Score for Risk Stratification of Patients With Acute Heart Failure at the Emergency Department. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2019</b> , 72, 198-207	0.7	3
53	Authors' response to Comment on adaptive increase in sample size when interim results are promising. <i>Statistics in Medicine</i> , <b>2011</b> , 30, 3302-3303	2.3	3
52	Optimal Sequential Screening Guidelines for Quantitative Risk Factors Measured with Error. <i>Journal of the American Statistical Association</i> , <b>1995</b> , 90, 19-26	2.8	3
51	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,	18.1	3
50	Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2608-2618	15.1	3
49	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e004945	5.8	3
48	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 709-716	3	3
47	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 95, 885-892	2.7	3



46	Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. <i>Open Heart</i> , <b>2021</b> , 8,	3	3
45	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 444-456	5	3
44	Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	3
43	Association between anthropometry and high blood pressure in a representative sample of preschoolers in madrid. <i>Revista Espanola De Cardiologia (English Ed )</i> , <b>2015</b> , 68, 477-84	0.7	2
42	RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2 (RIGHT-2): SAFETY AND EFFICACY OF TRANSDERMAL GLYCERYL TRINITRATE, A NITRIC OXIDE DONOR. <i>Emergency Medicine Journal</i> , <b>2016</b> , 33, e13.2-e14	1.5	2
41	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1704-1711	7	2
40	Does midlife obesity really lower dementia risk? - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 501-2	18.1	2
39	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 984-995	7.9	2
38	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008075	7.6	2
37	The Nature of the P Value. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2205-2206	59.2	2
36	Associations between change in blood pressure and functional outcome, early events and death: results from the Efficacy of Nitric Oxide in Stroke trial. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 2104-2109	1.9	2
35	Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEMI. <i>Revista Espanola De Cardiologia (English Ed )</i> , <b>2017</b> , 70, 817-824	0.7	1
34	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 453-459	6.4	1
33	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , <b>2020</b> , 43, 1352-1361	3.3	1
32	Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 899-900	8	1
31	A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials. <i>Trials</i> , <b>2013</b> , 14,	2.8	1
30	Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial.. <i>EClinicalMedicine</i> , <b>2022</b> , 44, 101274	11.3	1
29	Accounting For Non-Independent Observations In 2D Tables, With Application To Correcting For Family Clustering In Exposure-Risk Relationship Studies. <i>Journal of Modern Applied Statistical Methods</i> , <b>2002</b> , 1, 379-386	0.3	1

28	The Clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2021</b> ,	0.7	1
27	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 665-674	3.3	1
26	Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. <i>European Heart Journal</i> , <b>2021</b> , 42, 2052-2059	9.5	1
25	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 94, 53-60	2.7	1
24	Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. <i>International Journal of Cardiology</i> , <b>2021</b> , 327, 19-24	3.2	1
23	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , <b>2021</b> , 14, 1434-1446	5	1
22	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Translation to Russian. <i>Digital Diagnostics</i> , <b>2021</b> , 2, 119-169	1.8	1
21	Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 827-839	15.1	1
20	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , <b>2021</b> , 23, 100818	1.8	1
19	STATISTICAL REPORTING OF CLINICAL TRIALS WITH INDIVIDUAL CHANGES FROM ALLOCATED TREATMENT <b>1996</b> , 15, 249		1
18	The hope and the hazards of using compliance data in randomized controlled trials <b>1998</b> , 17, 303		1
17	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1129-1137	15.1	1
16	Re: "quality of reporting of observational longitudinal research". <i>American Journal of Epidemiology</i> , <b>2005</b> , 162, 1032-3; author reply 1033	3.8	0
15	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. <i>JACC: Cardiovascular Interventions</i> , <b>2022</b> , 15, 282-282	5	0
14	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , <b>2021</b> , 21, 218	4.7	0
13	Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial. <i>Stroke and Vascular Neurology</i> , <b>2021</b> , 6, 180-186	9.1	0
12	Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. <i>BMJ Open</i> , <b>2020</b> , 10, e034613	3	0
11	Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , <b>2021</b> , 14, 790-798	3.3	0

10	Covariate Adjustment in Cardiovascular Randomized Controlled Trials: Its Value, Current Practice, and Need for Improvement.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 297-305	7.9	0
9	Oseltamivir for influenza - Authors' reply. <i>Lancet, The</i> , <b>2016</b> , 387, 125	4.0	
8	The Use of Figures in Epidemiological Publications: A Survey of Current Practice and Consequent Recommendations <b>2012</b> , 71-83		
7	Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 92-99	3.3	
6	Statistical Essentials in the Design and Analysis of Clinical Trials 491-501		
5	Implications of Biomarker Discordance After Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2978-2980	15.1	
4	Statistical Essentials in the Design and Analysis of Clinical Trials <b>2016</b> , 296-300		
3	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , <b>2019</b> , 139, 422-423	16.7	
2	Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia. <i>American Journal of Cardiovascular Drugs</i> , <b>2021</b> , 21, 471-482	4	
1	Percutaneous coronary intervention for stable angina in ORBITA. <i>Lancet, The</i> , <b>2018</b> , 392, 26-27	4.0	